NASDAQ:VIRI Virios Therapeutics (VIRI) Stock Price, News & Analysis $0.22 -0.01 (-4.35%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.22▼$0.2450-Day Range$0.18▼$0.2952-Week Range$0.16▼$2.17Volume805,403 shsAverage Volume891,513 shsMarket Capitalization$4.24 millionP/E RatioN/ADividend YieldN/APrice Target$1.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Virios Therapeutics alerts: Email Address Virios Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside354.5% Upside$1.00 Price TargetShort InterestHealthy4.56% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.27) to ($0.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.36 out of 5 stars 3.5 Analyst's Opinion Consensus RatingVirios Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVirios Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Virios Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.56% of the outstanding shares of Virios Therapeutics have been sold short.Short Interest Ratio / Days to CoverVirios Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Virios Therapeutics has recently increased by 181.13%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVirios Therapeutics does not currently pay a dividend.Dividend GrowthVirios Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIRI. Previous Next 3.0 News and Social Media Coverage News SentimentVirios Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Virios Therapeutics this week, compared to 1 article on an average week.Search Interest7 people have searched for VIRI on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows3 people have added Virios Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Virios Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.20% of the stock of Virios Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.05% of the stock of Virios Therapeutics is held by institutions.Read more about Virios Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Virios Therapeutics are expected to grow in the coming year, from ($0.27) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Virios Therapeutics is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Virios Therapeutics is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVirios Therapeutics has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Virios Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Virios Therapeutics Stock (NASDAQ:VIRI)Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.Read More VIRI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIRI Stock News HeadlinesJuly 25 at 10:45 AM | markets.businessinsider.comOptimistic Buy Rating for Virios Therapeutics as IMC-2 Advances in Clinical Trials with Promising Phase 2 ResultsJuly 23, 2024 | globenewswire.comVirios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne CenterJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 22, 2024 | globenewswire.comVirios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyMay 20, 2024 | msn.comWhy Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day SessionMay 20, 2024 | investorplace.comWhy Is Virios Therapeutics (VIRI) Stock Down 44% Today?May 20, 2024 | msn.comVirios Therapeutics shares slid on pricing public offering of units to raise $1.7MMay 19, 2024 | globenewswire.comVirios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 18, 2024 | markets.businessinsider.comVirios Therapeutics Plans To Sell Up To $2.1 Mln In Shares Of Its Common Stock In Public OfferingMay 17, 2024 | marketwatch.comVirios Therapeutics Shares Tumble 35% on Stock OfferingMay 17, 2024 | globenewswire.comVirios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyMay 13, 2024 | markets.businessinsider.comMaintaining Hold on Virios Therapeutics Amid Financial Strains and Clinical Development RisksMay 13, 2024 | finance.yahoo.comVIRI: Results for Phase 2 Long COVID Trial Expected in 2H24…May 13, 2024 | finance.yahoo.comVirios Therapeutics, Inc. (NASDAQ:VIRI) Q1 2024 Earnings Call TranscriptMay 12, 2024 | uk.investing.comEarnings call: Virios Therapeutics reports on Q1 2024 progressMay 11, 2024 | msn.comVirios Reveals Figures, Corporate UpdateMay 9, 2024 | msn.comVIRI Stock Earnings: Virios Therapeutics Misses EPS for Q1 2024See More Headlines Receive VIRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VIRI CUSIPN/A CIK1818844 Webwww.virios.com Phone866-620-8655FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$1.00 High Stock Price Target$1.00 Low Stock Price Target$1.00 Potential Upside/Downside+354.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,300,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-127.42% Return on Assets-113.61% Debt Debt-to-Equity RatioN/A Current Ratio5.66 Quick Ratio5.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book1.10Miscellaneous Outstanding Shares19,258,000Free Float16,909,000Market Cap$4.24 million OptionableOptionable Beta1.61 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Gregory Duncan (Age 59)Chairman & CEO Comp: $566.92kDr. William L. Pridgen M.D. (Age 63)Founder & Director Comp: $35kMs. Angela Walsh (Age 57)CFO, SVP of Finance, Corporate Secretary & Treasurer Comp: $282.64kDr. R. Michael Gendreau M.D. (Age 68)Ph.D., Chief Medical Officer Comp: $364.94kMr. Ralph D. Grosswald M.P.H. (Age 55)Senior Vice President of Operations Comp: $274.69kMs. Carol Duffy Ph.D.Chief Scientific AdvisorMore ExecutivesKey CompetitorsConduit PharmaceuticalsNASDAQ:CDTLongeveronNASDAQ:LGVNApollomicsNASDAQ:APLMJanoneNASDAQ:ALTSIndaptus TherapeuticsNASDAQ:INDPView All CompetitorsInsidersWilliam PridgenBought 15,335 shares on 8/21/2023Total: $19,935.50 ($1.30/share)Gregory Scott DuncanBought 25,000 shares on 8/17/2023Total: $31,250.00 ($1.25/share)View All Insider Transactions VIRI Stock Analysis - Frequently Asked Questions How have VIRI shares performed this year? Virios Therapeutics' stock was trading at $0.5750 at the beginning of the year. Since then, VIRI stock has decreased by 61.7% and is now trading at $0.22. View the best growth stocks for 2024 here. How were Virios Therapeutics' earnings last quarter? Virios Therapeutics, Inc. (NASDAQ:VIRI) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. When did Virios Therapeutics IPO? Virios Therapeutics (VIRI) raised $30 million in an initial public offering (IPO) on Thursday, December 17th 2020. The company issued 3,000,000 shares at $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. How do I buy shares of Virios Therapeutics? Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIRI) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.